论文部分内容阅读
目的观察小剂量利妥昔单抗注射液治疗难治性原发免疫性血小板减少症(ITP)的临床疗效及不良反应。方法选择难治性ITP患者15例,均采用小剂量利妥昔单抗注射液100mg/次治疗,每周1次,连续治疗4周,观察其临床疗效、血小板计数及不良反应。结果 15例患者完全反应率为53.3%(8/15),总反应率为73.3%(11/15)。11例治疗有效的患者从给药第2周开始出现不同程度的血小板计数上升,起效时间为14~42d,中位数为29d。治疗过程中出现过敏反应1例,出现胃肠道反应2例,给予对症处理及减慢静脉滴注速度后症状缓解消失。结论小剂量利妥昔单抗注射液治疗难治性ITP效果确切,不良反应小。
Objective To observe the clinical efficacy and adverse reactions of low dose rituximab injection in refractory idiopathic thrombocytopenia (ITP). Methods Fifteen patients with refractory ITP were selected. All patients were treated with low dose rituximab 100mg once daily for 4 weeks. The clinical efficacy, platelet count and adverse reactions were observed. Results The complete response rate was 53.3% (8/15) in 15 patients and the overall response rate was 73.3% (11/15). Eleven patients with effective treatment began to have varying degrees of platelet count rise from the second week of treatment, the onset time was 14 ~ 42d, the median was 29d. During the course of treatment, one case had anaphylactic reaction and two cases had gastrointestinal reaction. Symptoms were relieved after symptomatic treatment and slowing down of intravenous infusion rate. Conclusion The low dose of rituximab injection for refractory ITP has definite effect and small adverse reaction.